Literature DB >> 10621921

A comparison of the efficacy of the alginate preparation, Gaviscon Advance, with placebo in the treatment of gastro-oesophageal reflux disease.

S Chatfield.   

Abstract

The aim of this study was to compare the efficacy of the sodium alginate preparation, Gaviscon Advance, with placebo in the relief of symptoms of reflux oesophagitis. This was a randomised, double-blind, parallel-group, multicentre study conducted at 13 GP centres in the UK. Patients aged between 18 and 70 years, who had experienced symptoms of reflux oesophagitis within the previous 24 h, and on two other occasions within the previous week, were recruited into the study. Patients were evaluated at baseline, and then reassessed after two and four weeks of treatment with sodium alginate or placebo, for symptoms of reflux oesophagitis in the previous 24 h. Patients were required to fill out a diary card twice daily, from which frequency and severity of symptoms were assessed, and the percentage of symptom-free days and nights calculated. Of the 100 patients recruited into the study, 98 received medication (safety population; placebo, n = 50; sodium alginate, n = 48) and 94 were eligible for inclusion in the intention-to-treat (ITT) population (placebo, n = 48; sodium alginate, n = 46). For this population, sodium alginate was assessed as significantly superior by both investigators and patients at week two (p < 0.001 and p = 0.004, respectively) and at week four (p = 0.001 and p < 0.001, respectively). Significantly more patients in the safety population on placebo withdrew from the study (40%) compared with sodium alginate (21%; p = 0.04), due primarily to lack of effect and adverse events. The sodium alginate preparation demonstrated a superior efficacy compared with placebo, which was achieved in a more acceptable volume of medication than a previous standard preparation, Liquid Gaviscon. The reduced dosage volume of the 'new' preparation (Gaviscon Advance) may be expected to improve patient compliance, and thereby increase treatment efficacy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10621921     DOI: 10.1185/03007999909114086

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  11 in total

1.  A comparison between sodium alginate and magaldrate anhydrous in the treatment of patients with gastroesophageal reflux symptoms.

Authors:  Edoardo G Giannini; Patrizia Zentilin; Pietro Dulbecco; Elena Iiritano; Claudio Bilardi; Edoardo Savarino; Carlo Mansi; Vincenzo Savarino
Journal:  Dig Dis Sci       Date:  2006-09-15       Impact factor: 3.199

2.  Alginates: From the ocean to gastroesophageal reflux disease treatment.

Authors:  Serhat Bor; İsmail Hakkı Kalkan; Altay Çelebi; Dinç Dinçer; Filiz Akyüz; Peter Dettmar; Hasan Özen
Journal:  Turk J Gastroenterol       Date:  2019-09       Impact factor: 1.852

Review 3.  Clinical response (remission of symptoms) in erosive and non-erosive gastro-oesophageal reflux disease.

Authors:  J Enrique Domínguez-Muñoz; Miguel Sobrino
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial 'acid pocket' in symptomatic GERD patients.

Authors:  M A Kwiatek; S Roman; A Fareeduddin; J E Pandolfino; P J Kahrilas
Journal:  Aliment Pharmacol Ther       Date:  2011-05-03       Impact factor: 8.171

Review 5.  Alginate therapy is effective treatment for GERD symptoms: a systematic review and meta-analysis.

Authors:  D A Leiman; B P Riff; S Morgan; D C Metz; G W Falk; B French; C A Umscheid; J D Lewis
Journal:  Dis Esophagus       Date:  2017-05-01       Impact factor: 3.429

6.  Alginate controls heartburn in patients with erosive and nonerosive reflux disease.

Authors:  Edoardo Savarino; Nicola de Bortoli; Patrizia Zentilin; Irene Martinucci; Luca Bruzzone; Manuele Furnari; Santino Marchi; Vincenzo Savarino
Journal:  World J Gastroenterol       Date:  2012-08-28       Impact factor: 5.742

Review 7.  Seaweed Polysaccharide Based Products and Materials: An Assessment on Their Production from a Sustainability Point of View.

Authors:  Nishith A Chudasama; Rosy Alphons Sequeira; Kinjal Moradiya; Kamalesh Prasad
Journal:  Molecules       Date:  2021-04-29       Impact factor: 4.411

8.  Gaviscon® vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direct comparative randomised trial.

Authors:  Denis Pouchain; Marc-André Bigard; François Liard; Marc Childs; Annick Decaudin; Donna McVey
Journal:  BMC Gastroenterol       Date:  2012-02-23       Impact factor: 3.067

9.  Assessment of the Safety and Efficacy of a Raft-Forming Alginate Reflux Suppressant (Liquid Gaviscon) for the Treatment of Heartburn during Pregnancy.

Authors:  Vicki Strugala; Julian Bassin; Valerie S Swales; Stephen W Lindow; Peter W Dettmar; Edward C M Thomas
Journal:  ISRN Obstet Gynecol       Date:  2012-11-04

10.  Evaluation of an Innovative Over-the-Counter Treatment for Symptoms of Reflux Disease: Quick-Dissolving Alginate Granules.

Authors:  Vicki Strugala; Peter W Dettmar; Edward C M Thomas
Journal:  ISRN Pharm       Date:  2012-12-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.